Biologics: Targets & Therapy (Nov 2021)
State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer
Abstract
Debora Basile,1 Francesca Simionato,1 Alessandro Cappetta,1 Silvio Ken Garattini,2 Giandomenico Roviello,3 Giuseppe Aprile1 1Department of Oncology, San Bortolo General Hospital, AULSS8 Berica, Vicenza, Italy; 2Department of Oncology, University Hospital, Udine, Italy; 3Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, ItalyCorrespondence: Giuseppe AprileDepartment of Oncology, AULSS8 Berica, Vicenza, ItalyEmail [email protected]: Gastric cancer (GC) is a complex and heterogeneous disease with poor prognosis and limited available treatment options. During recent years, several molecular stratifications have been proposed to optimize the overall treatment strategy for GC patients. Breakthroughs in cancer biology and in molecular profiling through DNA and RNA sequencing are now opening novel landscapes, leading to the personalization of molecular matched therapy. In particular, therapies against HER2, Claudine 18.2, Fibroblast Growth Factor Receptors (FGFR), and other molecular alterations could significantly improve survival outcomes in the advance phase of the disease. Furthermore, immunotherapy with checkpoint inhibitors also represents a promising option in a selected population. Hoping that precision oncology will enter soon in clinical practice, our review describes the state of the art of many novel pathways and the current evidence supporting the use of monoclonal antibodies implicated in GC treatment.Keywords: gastric cancer, precision oncology, HER2-inhibitors, Claudine 18.2 inhibitors, FGFR inhibitors
